[go: up one dir, main page]

WO2000001718A2 - Domaine catalytique ns4a et ns3 de l'hepatite c - Google Patents

Domaine catalytique ns4a et ns3 de l'hepatite c Download PDF

Info

Publication number
WO2000001718A2
WO2000001718A2 PCT/US1999/015035 US9915035W WO0001718A2 WO 2000001718 A2 WO2000001718 A2 WO 2000001718A2 US 9915035 W US9915035 W US 9915035W WO 0001718 A2 WO0001718 A2 WO 0001718A2
Authority
WO
WIPO (PCT)
Prior art keywords
seq
ns4a
hepatitis
polypeptide
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1999/015035
Other languages
English (en)
Other versions
WO2000001718A3 (fr
Inventor
Ben M. Dunn
Marina Bukhtiyarova
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Florida
Original Assignee
University of Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Florida filed Critical University of Florida
Priority to AU48552/99A priority Critical patent/AU4855299A/en
Publication of WO2000001718A2 publication Critical patent/WO2000001718A2/fr
Publication of WO2000001718A3 publication Critical patent/WO2000001718A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/503—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
    • C12N9/506—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses derived from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Definitions

  • Hepatitis C is an infectious disease that infects nearly 2% of Americans, and even higher levels of the populations of other countries. Previously, this virus was spread mainly by transfusion with infected blood, due to the lack of a diagnostic test prior to 1990. The major mechanism of transmission currently is by IV drug use, with sexual transmission a secondary factor. This virus causes chronic disease in the liver, leading to cirrhosis and potential liver failure. In about 10% of infected individuals, carcinoma of the liver is also an outcome. By the year 2015, it is estimated that 400,000 Americans will have advanced stages of liver disease caused by hepatitis C and that 40,000 will die annually. Thus, hepatitis C has emerged as the next significant anti-viral drug target, following the successful development of anti-HIV compounds.
  • the virus responsible for hepatitis C is a positive-stranded RNA virus that produces progeny virus in a mechanism similar to that of the HIV system; the viral message is translated to produce a viral "polyprotein" containing a number of functional proteins connected head-to-tail. Embedded within this large polyprotein are two putative proteolytic enzymes, NS2 and NS3.
  • the NS3 protein includes a "catalytic domain" of 182 amino acids that bears a sequence relationship to members of the trypsin family of serine proteases. NS3 is responsible for cleavage of four of the sites within the viral polyprotein that must be cut to separate the functional units.
  • NS3 protease Viral replication is not possible without these cuts; thus, the activity of NS3 protease is a target for anti-viral drug discovery.
  • U.S. Patent Nos. 5,371,017 and 5,712,145 describe the cloning and expression of hepatitis C protease involved in polyprotein processing.
  • U.S. Patent No. 5,739,002 describes a method for reproducing in vitro the proteolytic activity of the NS3 protease.
  • the 182 amino acid NS3 catalytic domain which is only about one-third of the entire NS3 protein, has been cloned and expressed by several groups, and shown to possess the catalytic activity necessary to achieve the four cleavages.
  • the efficiency of the processing is very low, and the 182-residue protein is very unstable and insoluble. Thus, working with this system is difficult at best. It has been discovered by a variety of workers (Failla et al., 1984; Lin et al, 1995; Shimizu et al, 1996; and Bianchi et al, 1997) that another portion of the viral polyprotein, the NS4A fragment, is necessary to increase the activity of the NS3 catalytic domain.
  • the NS4A segment of the hepatitis polyprotein is downstream of the NS3 protein, and is separated from the NS3 catalytic serine protease domain by a separate domain that possesses helicase activity.
  • U.S. Patent No. 5,843,752 describes fusion complexes between NS3 and NS4A.
  • the subject invention concerns compositions and methods of use of modified domains of the polyprotein of the hepatitis C virus.
  • the polypeptides of the invention are directed to modified forms of the NS3 and NS4A domains of the polyprotein covalently linked together.
  • an NS4A fragment is covalently attached to the N-terminal end of an NS3 domain.
  • the subject invention also concerns polynucleotides that encode the NS3/NS4A polypeptides of the invention.
  • the invention also pertains to methods of preparing the subject polypeptides and methods for screening for compounds that inhibit the serine protease activity of the NS3 protein.
  • Figure 1 shows the amino acid sequence of an NS3 clone of the IB genotype. Amino acid residues deleted for the NS4A/NS3 construct of the subject invention are shown underlined.
  • Figure 2 shows the amino acid sequence of an NS4A/NS3 fusion construct according to the subject invention.
  • Figure 3A and 3B show an NS3 nucleic acid sequence and an amino acid sequence encoded by the nucleic acid sequence, respectively.
  • Figure 3B includes a histidine tag sequence consisting of about the first 23 amino acids which is attached to allow for easier purification of the protein using Ni Agarose matrix.
  • Figure 4A and 4B show an NS4 S3 fusion construct nucleic acid sequence and an amino acid sequence encoded by the nucleic acid sequence, respectively.
  • the polypeptide shown in Figure 4B includes a histidine tag sequence consisting of about the first 23 amino acids which is attached to allow for easier purification of the protein using Ni Agarose matrix.
  • the subject invention concerns polynucleotides which encode polypeptides comprising an NS3 catalytic domain, or a catalytic fragment or variant thereof, of hepatitis C serine protease covalently attached to a peptide derived from an NS4A domain.
  • the subject invention also concerns the NS4A/NS3 polypeptides encoded by the polynucleotides of the invention.
  • an NS4A/NS3 construct was prepared using an oligonucleotide primer to produce a polynucleotide encoding the NS4A/NS3 polypeptide that had several amino acid residues of an NS4A fragment added to the amino terminus of an NS3 catalytic domain ( Figure 2).
  • one amino acid of the NS3 sequence was changed, based on the structure, to introduce a more polar amino acid to improve solubility. Five residues of the NS3 catalytic domain were also removed in the exemplified construct.
  • one aspect of the present invention concerns constructs where an NS4A fragment, which is normally associated with the C-terminal end of the NS3 fragment, is placed on the N-terminal end of NS3.
  • an NS4A fragment which is normally associated with the C-terminal end of the NS3 fragment, is placed on the N-terminal end of NS3.
  • IB genotype was utilized in one of the constructs exemplified herein, all other hepatitis C genotypes are contemplated within the scope of the present invention.
  • a polynucleotide was prepared that encodes a fusion construct comprising a histidine tag sequence for Ni Agarose purification covalently linked to the amino terminus of an NS3 catalytic domain. From that fusion construct, an NS4A peptide sequence (SEQ ID NO. 7) was inserted between the histidine tag sequence and the start of the NS3 domain sequence ( Figure 4B). The histidine tag sequence can be optionally removed or deleted from the NS4A/NS3 construct.
  • a plasmid encoding the modified polypeptide of the invention was expressed in E.coli in high levels in the form of insoluble inclusion bodies.
  • the preparation of inclusion bodies included isolation via centrifugation through sucrose gradients. The resulting material was solubilized and the protein was re-folded by dialysis in several steps to yield a solution at pH 8.0. An aliquot of this preparation was able to cleave a peptide substrate based on the hepatitis 5A/5B cleavage site.
  • the methods and compositions of the present invention yield several milligrams of protein per liter of expression medium.
  • the NS4A NS3 constructs of the present invention exhibit properties of the non-covalent NS3 and NS4A complex with respect to catalytic activity and ligand binding, but with superior stability and solubility.
  • the subject invention provides for the expression of the hepatitis C NS3 serine protease domain in greater amounts and in higher purity with fewer steps.
  • the NS4/NS3 protein produced according to the present invention is more stable and considerably more soluble than the NS3 catalytic domain alone.
  • the NS4A/NS3 polypeptides of the present invention can be used for direct screening of potential antiviral drug candidates.
  • the subject invention also concerns methods for screening for compounds that can be used in diagnostic or therapeutic applications for persons infected with the hepatitis C virus.
  • the recombinant polypeptides of the invention can be used to screen for compounds that inhibit the hepatitis C serine protease.
  • a method of the present invention comprises contacting an NS4A/NS3 polypeptide of the subject invention with a selected composition and then determining whether the composition binds to or inhibits the activity of the NS4/NS3 polypeptide.
  • compounds that inhibit hepatitis C serine protease are also contemplated within the scope of the present invention. These compounds can be readily identified using the compositions and screening methods according to the present invention.
  • any of a number of different nucleotide sequences can be used, based on the degeneracy of the genetic code, to produce the modified proteins described herein. Accordingly, any nucleotide sequence which encodes the proteins described herein comes within the scope of this invention. Also, as described herein, fragments and variants of the subject NS3 domain covalently linked to the NS4A peptide are an aspect of the invention so long as such fragments and variants retain serine protease activity substantially the same as wild type NS3 protein. Variants include those sequences in which amino acid substitutions, insertions and/or deletions have been introduced that change the variant sequence from the wild type sequence.
  • NS4A peptides within the scope of the invention include those peptides specifically exemplified herein, as well as peptides having additional amino acids added to or deleted from either or both ends of the peptide sequence. For example, 10 to 20 amino acids can be added to either or both ends of the peptide. Preferably, the amino acids added are the same as the corresponding amino acids in the NS4A domain.
  • nucleic acid and “polynucleotide sequence” refer to a deoxyribonucleotide or ribonucleotide polymer in either single- or double-stranded form, and unless otherwise limited, would encompass known analogs of natural nucleotides that can function in a similar manner as naturally-occurring nucleotides.
  • the polynucleotide sequences include both the DNA strand sequence that is transcribed into RNA and the RNA sequence that is translated into protein.
  • the polynucleotide sequences include both full-length sequences as well as shorter sequences derived from the full-length sequences.
  • polynucleotide sequence includes the degenerate codons of the native sequence or sequences which may be introduced to provide codon preference in a specific host cell. Allelic variations of the exemplified sequences also come within the scope of the subject invention.
  • the polynucleotide sequences falling within the scope of the subject invention further include sequences which specifically hybridize with the exemplified sequences under stringent conditions.
  • the nucleic acid includes both the sense and antisense strands as either individual strands or in the duplex.
  • hybridize or “hybridizing” refer to the binding of two single-stranded nucleic acids via complementary base pairing.
  • hybridizing specifically to refers to binding, duplexing, or hybridizing of a molecule to a nucleotide sequence under stringent conditions when that sequence is present in a preparation of total cellular DNA or RNA.
  • stringent conditions refers to conditions under which a polynucleotide will hybridize to another sequence, but not to sequences having little or no homology to the sequence. Generally, stringent conditions are selected to be about 5°C lower than the thermal melting point (Tm) for the specific sequence at a defined ionic strength and pH. The Tm is the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a complementary polynucleotide.
  • Tm thermal melting point
  • stringent conditions will be those in which the salt concentration is at least about 0.1 to 1.0 N Na ion concentration at a pH of about 7.0 to 7.5 and the temperature is at least about 60°C for long sequences (e.g., greater than about 50 nucleotides) and at least about 42 °C for shorter sequences (e.g., about 10 to 50 nucleotides).
  • a further aspect of the present invention are antibodies that are raised by immunization of an animal with a purified protein of the subject invention.
  • Both polyclonal and monoclonal antibodies can be produced using standard procedures well known to those skilled in the art using the proteins of the subject invention as an immunogen (see, for example, Monoclonal Antibodies: Principles and Practice, 1983; Monoclonal Hybridoma Antibodies: Techniques and Applications, 1982; Selected Methods in Cellular Immunology, 1980; Immunological Methods, Vol. II, 1981 ; Practical Immunology, and Kohler et al., 1975.
  • Fab', F(ab') 2 , and Fv fragments may be obtained by conventional techniques, such as proteolytic digestion of the antibodies by papain or pepsin, or through standard genetic engineering techniques using polynucleotide sequences that encode binding fragments of the antibodies of the subject invention.
  • Viral RNA was isolated from lOO ⁇ L of human serum obtained from patients at Shands Teaching Hospital Liver Unit. Reverse Transcription PCR was carried out using an upper primer beginning (5' end) at nucleotide number 2920 of the full sequence, and a lower primer beginning (3' end) at nucleotide number 3897. Amplification was the achieved by PCR with Taq polymerase using primers to produce a product of 990bp. This fragment was cloned into the pGEM-T vector. Individual clones were selected for DNA sequence analysis using standard dideoxy sequencing techniques.
  • PCR amplification using sequence-specific primers was used to obtain a 0.58kb DNA fragment coding for 181 amino acids of the NS3 region.
  • This region contains the catalytic residues of the serine protease domain. This was initially cloned into the pETl 1 vector using the BamHl and Ndel restriction sites. This vector was used for further amplification as described below.
  • the regions of the NS3 and NS4A proteins were genetically engineered to produce a recombinant protein having portions of the NS3 and NS4A domains covalently connected into one continuous protein chain.
  • five residues from the amino terminus of the NS3 catalytic domain were deleted.
  • the sequence of the original NS3 clone of the IB genotype is shown in Figure 1.
  • the amino acid residues deleted are MAPIT.
  • the sixth amino acid of the NS3 sequence, proline (P) was changed to a lysine (K).
  • a sequence of the NS4A fragment (amino acid sequence: MSVVIVGRIVLS; SEQ ID NO. 12) was also added.
  • Example 1- Expression of protein A recombinant NS4A/NS3 construct encoding the amino acid sequence shown in Figure 2 was constructed by PCR amplification from the pETl 1 vector by using a primer designed for the 5' end that included the additional amino acids and restriction sites. The resulting DNA was cloned into the pET28b vector, which also contains the His(6) tag and a thrombin cleavage site at the amino terminal end. This vector was transformed into BL21DE3 cells, and ampicillin-resistant clones were picked and grown in liquid culture. Glycerol was added to 20% and the samples frozen.
  • some of the frozen culture was scraped out using a spatula and used to inoculate a culture of M9CA media for overnight growth in a 37 °C shaker. Twenty mis of the overnight culture were used to inoculate a 1L Luria Broth media containing 50 ⁇ l/ml ampicillin and grown in a 4L flask in a 37°C shaker to an O.D. of 0.5-1.0.
  • Induction of expression was achieved by adding l .OmM IPTG, and growth was continued for three hours.
  • the cultures were transferred to 250ml polypropylene bottles and spun in a J14 rotor for 10 min at 8000 rpm to pellet the cells. The supernatant was poured off and the pellets were re-suspended in 10 ml of 50mM Tris pH 7.4, 160ml NaCl, ImM MgCl 2 (TN buffer). Cells were spun again and re-suspended in the same buffer, using 4.2 mis per gram of cells. DNase stock (60U/ml) was added to re-suspend cells at a concentration of 80U/ml.
  • Triton X-100 (TN + Triton Buffer) and again applied over a 27% sucrose cushion in two Corex tubes.
  • the tubes were spun in a JS-13.1 rotor for 30 min at 8500 rpm. The supernatant was discarded and the tubes inverted over Kimwipes to drain.
  • the inclusion bodies were stored at -20°.
  • the buffer was changed to one of pH 8.0, containing 2 mM DTT and 5% isopropanol and dialysis continued overnight at 4 ° .
  • Final dialysis was done with 50 mM Tris-HCl pH 8.0, containing 2 mM DTT and 5% isopropanol.
  • the material obtained has the ability to cleave substrates of several types, including proteins derived from the hepatitis polyprotein, and peptide substrates either with or without fluorescent groups for protection.
  • the activity obtained is at or above
  • a cell culture containing vector encoding a recombinant NS4A/NS3 construct of the present invention was grown overnight at 37 °C in LB media containing 25 mg/mL Kanamycin.
  • the cells were allowed to grow at 22 °C for 4 hours and then harvested by centrifugation at 8500 rpm for 20 minutes. Once pelleted, cells can be stored at -20 °C, if necessary.
  • the cells were resuspended in Buffer A (0.1 M K. Phosphate, 13% glycerol, 1 M NaCl, 0.05% Triton X-100, 20 mM Imidazole pH 7.5) at 20 mL per 1 L of culture. DNase was added to a final concentration of 80 U/mL.
  • the cells were then French pressed at 1000 psi 3 times. Cell lysate was clarified by centrifugation at 14,000 rpm for 25 minutes using a JA-20 rotor. The cell lysate can be stored at -20 °C until required for Ni-agarose.
  • Ni Agarose purification One mL of a Ni-agarose slurry was equilibrated with Buffer A (described above). 20 mL of cell lysate was incubated with the resin for 15-20 minutes with intermittent shaking. The lysate was allowed to elute off, but stored for a consecutive incubation with the resin. The resin was subsequently washed with 20 mL Buffer A at least four times to ensure the removal of contaminating proteins. The protein was initially eluted with 5 mL of Buffer B (0.1 M K. Phosphate, 13% glycerol, 0.2M imidazole), which can be mixed with the resin, and then another 5 mL is used to ensure all protein is eluted. The protein can be stored at -80 °C until required for gel filtration purification.
  • Buffer A 0.1 M K. Phosphate, 13% glycerol, 0.2M imidazole

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des domaines modifiés de la polyprotéine du virus de l'hépatite C. Les polypeptides selon l'invention sont destinés à des formes modifiées des domaines NS3 et NS4A de ladite polyprotéine. Dans un mode de réalisation, la fraction NS4A est liée par covalence au domaine catalytique NS3. La fraction NS4A est liée à l'extrémité N-terminale de NS3. L'invention concerne également des polynucléotides qui codent pour les polypeptides NS3/NS4A. L'invention concerne également des méthodes de préparation desdits polypeptides et des méthodes de criblage de composés qui inhibent l'activité de la sérine-protéase de la protéine NS3.
PCT/US1999/015035 1998-07-02 1999-07-02 Domaine catalytique ns4a et ns3 de l'hepatite c Ceased WO2000001718A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU48552/99A AU4855299A (en) 1998-07-02 1999-07-02 Ns4a-ns3 catalytic domain of hepatitis c

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9167598P 1998-07-02 1998-07-02
US60/091,675 1998-07-02

Publications (2)

Publication Number Publication Date
WO2000001718A2 true WO2000001718A2 (fr) 2000-01-13
WO2000001718A3 WO2000001718A3 (fr) 2000-04-20

Family

ID=22229082

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/015035 Ceased WO2000001718A2 (fr) 1998-07-02 1999-07-02 Domaine catalytique ns4a et ns3 de l'hepatite c

Country Status (2)

Country Link
AU (1) AU4855299A (fr)
WO (1) WO2000001718A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7491808B2 (en) 2000-06-15 2009-02-17 Novartis Vaccines And Diagnostics, Inc. HCV non-structural protein mutants and uses thereof
EP2392589A3 (fr) * 2005-11-11 2012-06-20 Vertex Pharmaceuticals Incorporated Variantes du virus de l'hépatite C
US8501450B2 (en) 2005-11-11 2013-08-06 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843752A (en) * 1995-05-12 1998-12-01 Schering Corporation Soluble active hepatitis C virus protease
IT1277914B1 (it) * 1995-08-22 1997-11-12 Angeletti P Ist Richerche Bio Procedimento per produrre - in forma pura e in quantita' elevate - polipeptidi con l'attivita' proteolitica della proteasi ns3 di hcv, e
WO1999028482A2 (fr) * 1997-11-28 1999-06-10 Schering Corporation Complexes recombinants monocatenaires de la protease ns3 et du peptide co-facteur ns4a du virus de l'hepatite c (vhc)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7491808B2 (en) 2000-06-15 2009-02-17 Novartis Vaccines And Diagnostics, Inc. HCV non-structural protein mutants and uses thereof
EP2392589A3 (fr) * 2005-11-11 2012-06-20 Vertex Pharmaceuticals Incorporated Variantes du virus de l'hépatite C
US8501450B2 (en) 2005-11-11 2013-08-06 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants

Also Published As

Publication number Publication date
WO2000001718A3 (fr) 2000-04-20
AU4855299A (en) 2000-01-24

Similar Documents

Publication Publication Date Title
US6653127B1 (en) Single-chain recombinant complexes of hepatitis C virus NS3 protease and NS4A cofactor peptide
Suzich et al. Hepatitis C virus NS3 protein polynucleotide-stimulated nucleoside triphosphatase and comparison with the related pestivirus and flavivirus enzymes
CA2226293C (fr) Fragments de la proteine ns3 du virus de l'hepatite c presentant une activite de l'helicase et une meilleure solubilite
WO1991015575A1 (fr) Protease du virus de l'hepatite c
Hirowatari et al. Two proteinase activities in HCV polypeptide expressed in insect cells using baculovirus vector
WO1994018331A2 (fr) Proteines de fusion comportant un site de coupure reconnu par une protease virale de plante
EP0846164B1 (fr) Procede pour tester l'activite proteolytique de polypeptides ayant une activite de protease hcv ns3 et peptides substrats a utiliser dans cette methode.
EP0638122A1 (fr) Sequence de l'adn complementaire du serotype 1 du virus de la dengue (souche singapour)
CA2070952A1 (fr) Gene du virus de l'hepatite c ou fragment dudit gene, polypeptide code par le gene
US5800982A (en) Antigenic peptides for growing hepatitis C virus, kit comprising the same and methods for its grouping using the same
WO2000001718A2 (fr) Domaine catalytique ns4a et ns3 de l'hepatite c
AU768177B2 (en) Hepatitis C virus NS5B compositions and methods of use thereof
JP3878132B2 (ja) 精製活性型ｈｃｖｎｓ２／３プロテアーゼ
CA2264487A1 (fr) Polypeptides solubles a activite de serine protease ns3 du virus de l'hepatite c et leur procede de preparation et d'isolement
Ye et al. Two cis-acting elements in negative RNA strand of hepatitis C virus involved in synthesis of positive RNA strand in vitro
Leong et al. Efficient expression and purification of a protease from the common cold virus, human rhinovirus type 14
Hwang et al. Molecular cloning, expression, and purification of nuclear inclusion A protease from tobacco vein mottling virus
KR0154494B1 (ko) Hcv 코아 단백질의 융합단백질 및 이의 제조방법
KR100437889B1 (ko) 세망내피증 바이러스의 역전사 효소 및 이를 생산하는 방법
AU2002224688B2 (en) Purified active HCV NS2/3 protease
JPH05192160A (ja) Ｃ型肝炎ウイルスゲノムＲＮＡ、ｃＤＮＡ及びポリペプチド
WO1990015075A1 (fr) PRODUITS GENIQUES DE HTLV-1 env EXPRIMES DANS $i(E. coli)
CN100410387C (zh) 丙型肝炎病毒NS5b聚合酶细胞外分子复制模型及其用途
US5756333A (en) Recombinant production of lactoperoxidase
JPWO1999043792A1 (ja) ヒトｃ型肝炎ウイルスのｒｎａ依存性ポリメラーゼ活性を有する組換え型タンパク及びその製造方法

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AU BA BB BG BR CA CN CU CZ EE GD GE HR HU ID IL IN IS JP KP KR LC LK LR LT LV MG MK MN MX NO NZ PL RO SG SI SK SL TR TT UA US UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AU BA BB BG BR CA CN CU CZ EE GD GE HR HU ID IL IN IS JP KP KR LC LK LR LT LV MG MK MN MX NO NZ PL RO SG SI SK SL TR TT UA US UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

122 Ep: pct application non-entry in european phase